- Home
- TCRX vs CLYM Comparison
TCRX vs CLYM Comparison
Compare TCRX & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- CLYM
- Stock Information
- Founded
- TCRX 2018
- CLYM 2018
- Country
- TCRX United States
- CLYM United States
- Employees
- TCRX N/A
- CLYM N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- CLYM
- Sector
- TCRX Health Care
- CLYM
- Exchange
- TCRX Nasdaq
- CLYM NYSE
- Market Cap
- TCRX 90.5M
- CLYM 83.1M
- IPO Year
- TCRX 2021
- CLYM 2021
- Fundamental
- Price
- TCRX $1.27
- CLYM $1.19
- Analyst Decision
- TCRX Strong Buy
- CLYM
- Analyst Count
- TCRX 7
- CLYM 0
- Target Price
- TCRX $9.86
- CLYM N/A
- AVG Volume (30 Days)
- TCRX 389.5K
- CLYM 125.8K
- Earning Date
- TCRX 05-06-2025
- CLYM 05-19-2025
- Dividend Yield
- TCRX N/A
- CLYM N/A
- EPS Growth
- TCRX N/A
- CLYM N/A
- EPS
- TCRX N/A
- CLYM N/A
- Revenue
- TCRX $4,421,000.00
- CLYM N/A
- Revenue This Year
- TCRX $47.30
- CLYM N/A
- Revenue Next Year
- TCRX $74.30
- CLYM N/A
- P/E Ratio
- TCRX N/A
- CLYM N/A
- Revenue Growth
- TCRX N/A
- CLYM N/A
- 52 Week Low
- TCRX $1.02
- CLYM $1.05
- 52 Week High
- TCRX $9.69
- CLYM $10.23
- Technical
- Relative Strength Index (RSI)
- TCRX 37.62
- CLYM N/A
- Support Level
- TCRX $1.32
- CLYM N/A
- Resistance Level
- TCRX $1.65
- CLYM N/A
- Average True Range (ATR)
- TCRX 0.12
- CLYM 0.00
- MACD
- TCRX -0.02
- CLYM 0.00
- Stochastic Oscillator
- TCRX 0.00
- CLYM 0.00
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.